Neuroinflammation therapeutics: MITI 101 monoclonal antibody preventing innate immune cells from entering the brain; targeting Alzheimer’s; partnered with University of Rhode Island; cumulative $30M Series A plus $5M ADDF strategic
No detailed funding rounds available.
Total known funding: